Toxicity and Outcomes Associated With Reduced-Dose Post-Transplant Cyclophosphamide

Presenter/Author Information

• Michael Williams PharmD, BCOP, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
• Erin Franzen PharmD, BCOP, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
• Shanze Arshad, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate Health / University of Kentucky College of Medicine
• Brittany Mejaki PharmD, BCOP, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
• Syed N. Haider MD, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
• Syed A. Abutalib MD, Transplant and Cellular Therapy, Aurora St. Luke's Medical Center, Advocate HealthFollow
• Sherjeel Sana MD, Transplant and Cellular Therapy, Advocate Lutheran General Hospital, Advocate HealthFollow
• Stephen Medlin DO, Transplant and Cellular Therapy, Inova Schar Cancer InstituteFollow
• Zartash Gul MD, Transplant and Cellular Therapy, Inova Schar Cancer InstituteFollow

Recommended Citation

Williams M, Franzen E, Arshad S, et al. Toxicity and Outcomes Associated With Reduced-Dose Post-Transplant Cyclophosphamide. J Patient Cent Res Rev. 2025;12:283-284. doi: 10.17294/2330-0698.2248

Affiliations

Aurora St. Luke's Medical Center, Advocate Lutheran General Hospital

Presentation Notes

Oral presentation at Scientific Day; May 21, 2025; Park Ridge, IL. https://institutionalrepository.aah.org/sciday/2025/judged3/3

Document Type

Abstract